-
Views
-
Cite
Cite
Relugolix, American Journal of Health-System Pharmacy, Volume 78, Issue 9, 1 May 2021, Pages 762–763, https://doi.org/10.1093/ajhp/zxab036
Close - Share Icon Share
Extract
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist.
Class: 68:18.04 • Antigonadotropins (AHFS primary)Brands: Orgovyx®
Uses
Relugolix has the following uses:
...
Dosage and Administration
General.
Relugolix is available in the following dosage form(s) and strength(s):
...
Dosage.
It is essential that the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Adults.
Dosage and Administration.
...
Cautions
Contraindications.
...
Warnings/Precautions.
QT/QTc Interval Prolongation.
Androgen deprivation therapy such as relugolix may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.
Embryo-fetal Toxicity.
The safety and efficacy of relugolix have not been established in females. Based on findings in animals and mechanism of action, relugolix can cause fetal harm and loss of pregnancy when administered to a pregnant female. In an animal reproduction study, oral administration of relugolix to pregnant rabbits during the period of organogenesis caused embryo-fetal lethality at maternal exposures that were 0.3 times the human exposure at the recommended dose of 120 mg daily based on area under the concentration-time curve (AUC). Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of relugolix.
Comments